Glucagon-like peptide-1 receptor agonists and risk for hematologic malignancies: a multicenter propensity score-matched analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Hematologic Malignancy Risk With Glucagon-Like Peptide-1 Receptor Agonists: A Multicenter Propensity Score–Matched Study

  • By

  • Pratik Shah

  • Adit Singhal

  • Tsu Hsien Wang

  • Albert Ko

  • Yu-Cheng Chang

  • Anita Ng

  • Andrew Shih

  • Yuan Ping Hsia

  • Cho-Hung Chiang

  • Cho-Han Chiang

  • October 12, 2026

Share

  • 1

    This retrospective TriNetX study used propensity score matching to compare hematologic malignancy incidence among adults with type 2 diabetes initiating GLP-1RAs, DPP-4 inhibitors, or SGLT2 inhibitors

  • 2

    Among 68,949 matched pairs, GLP-1RA use was not significantly associated with any assessed hematologic malignancy compared with DPP-4 inhibitor use.

  • 3

    Among 71,391 matched pairs, GLP-1RA use was associated with lower incidence of NHL, MPN, and Hodgkin lymphoma than SGLT2 inhibitor use.

  • 4

    Compared with SGLT2 inhibitors, GLP-1RAs were not significantly associated with differences in myeloid or lymphoid leukemia, plasma cell neoplasms, or MDS.

  • 5

    Exploratory analyses found no significant differences in NHL subtypes between GLP-1RA users and either active comparator group.

Original Source(s)

Glucagon-like peptide-1 receptor agonists and risk for hematologic malignancies: a multicenter propensity score-matched analysis

  • by Pratik Shah, Adit Singhal, Tsu Hsien Wang, Albert Ko, Yu-Cheng Chang, Anita Ng, Andrew Shih, Yuan Ping Hsia, Cho-Hung Chiang, Cho-Han Chiang

  • October 12, 2026

Related Content

Association of Adjuvant Radiotherapy De-Escalation With Outcomes Following Oncoplastic Breast-Conserving Surgery

Improving survival and narrowing age disparities in mantle cell lymphoma across therapeutic eras

2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new antibody drug conjugate treatment options in first line triple negative breast cancer.

  • October 15, 2026

  • 1 min